Complementary to its impact on CD4+ T-cell CNS autoimmunity, our findings further suggest that HGF treatment could be exploited to control CD8+ T-cell-mediated, MHC I-restricted autoimmune dysfunctions such as MS. Here, CD4 is linked to myeloid sarcoma.